The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer

Launched by ANHUI PROVINCIAL HOSPITAL · Dec 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how useful certain imaging measurements, called Apparent Diffusion Coefficients (ADC), are in diagnosing prostate cancer in men. The researchers want to find out if these measurements can help improve the detection of significant prostate cancer, which is classified as having a Gleason score of 3+4 or higher. They are specifically looking at men who have already had an MRI scan with a score of 3 or higher, indicating a higher chance of cancer.

To be eligible for the trial, participants must be men aged 65 to 74 who have reasons for needing a prostate biopsy, have a specific level of a blood test called PSA, and have undergone a clear and readable MRI scan. Those who have had previous prostate surgeries, other cancers, or certain health issues that prevent MRI or biopsy are not eligible. If you join the trial, you will undergo additional assessments to help determine the effectiveness of these imaging techniques in diagnosing prostate cancer. Your participation will contribute to improving cancer detection methods for other patients in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. The patient met at least one indication of prostate biopsy (Chinese expert consensus on prostate biopsy (2022 edition) https://rs.yiigle.com/cmaid/1442948 );
• • 2. Serum PSA test was completed in the patient with tPSA \< 100 ng/ml;
• • 3. Primary prostate tumor lesion, no history of other tumors;
• • 4. Completed 3.0T bpMRI examination, PI-RADS score ≥3 score, the image is clear and readable;
• • 5. Patients fully understand the relevant contents of the study and voluntarily sign the informed consent.
• Exclusion Criteria:
• • 1. The patient has contraindications for MRI;
• • 2. PI-RADS 1-2 of bpMRI;
• • 3. The patient had contraindications to prostate biopsy or explicitly refused biopsy;
• • 4. bpMRI indicated that the patient had multiple lymph nodes or bone metastases;
• • 5. Previous prostate-related surgery;
• • 6. The patient refused to sign the informed consent.